These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26421728)

  • 1. Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.
    Aprile G; Giuliani F; Lutrino SE; Fontanella C; Bonotto M; Rihawi K; Fasola G
    Clin Colorectal Cancer; 2016 Mar; 15(1):7-15. PubMed ID: 26421728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
    Ron DA; Vera R; Labandeira CM; Manrique MCA; Núñez MÁ; Cid NG; Mata JG; Montes AF
    Clin Transl Oncol; 2020 Aug; 22(8):1205-1215. PubMed ID: 31898053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
    Stein A; Atanackovic D; Hildebrandt B; Stübs P; Brugger W; Hapke G; Steffens CC; Illerhaus G; Bluemner E; Stöhlmacher J; Bokemeyer C
    Br J Cancer; 2015 Sep; 113(6):872-7. PubMed ID: 26335608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in combination chemotherapy for colorectal cancer.
    Goetz MP; Grothey A
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):627-37. PubMed ID: 15270666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
    Hurwitz H; Kabbinavar F
    Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance strategy in metastatic colorectal cancer: A systematic review.
    Esin E; Yalcin S
    Cancer Treat Rev; 2016 Jan; 42():82-90. PubMed ID: 26608114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metastatic colorectal cancer: To stop or not to stop?].
    Artru P; Bennouna J; Lievre A; Ducreux M; Lledo G
    Bull Cancer; 2018 Apr; 105(4):408-414. PubMed ID: 29477654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
    Heinemann V; Hoff PM
    Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.
    Sunakawa Y; Bekaii-Saab T; Stintzing S
    Cancer Treat Rev; 2016 Apr; 45():97-104. PubMed ID: 27002945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy for colorectal cancer: which regimen and which patients?
    Mikhail S; Bekaii-Saab T
    Drugs; 2015 Nov; 75(16):1833-42. PubMed ID: 26377935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
    Okines A; Cunningham D
    Eur J Cancer; 2009 Sep; 45(14):2452-61. PubMed ID: 19643598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of maintenance therapy and complete discontinuation for therapeutic management of non-resectable metastatic colorectal cancer].
    Senellart H; Hiret S; Guerin-Meyer V; Bennouna J
    Bull Cancer; 2014 Jun; 101(6):619-25. PubMed ID: 24977450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.
    Varadhachary GR; Hoff PM
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S40-2. PubMed ID: 16399430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
    Xu W; Gong Y; Kuang M; Wu P; Cao C; Chen J; Tang C
    Clin Drug Investig; 2017 Feb; 37(2):155-165. PubMed ID: 27665469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
    Komatsu Y; Ishioka C; Shimada K; Yamada Y; Gamoh M; Sato A; Yamaguchi T; Yuki S; Morita S; Takahashi S; Goto R; Kurihara M
    BMC Cancer; 2015 Sep; 15():626. PubMed ID: 26353772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.